Your search for supplemental oxygen returned 57 results

Both randomized, placebo-controlled trials are expected to enroll approximately 1000 hospitalized patients.

The ACTT-2 study began on May 8 and included more than 1000 patients.

The placebo-controlled ACTT 3 trial will evaluate the efficacy and safety of remdesivir in combination with interferon beta-1a in more than 1000 hospitalized COVID-19 patients.

The patient, a 74-year-old female, presented to the ER after experiencing a low grade fever, cough, and shortness of breath for 2 days.

Dexamethasone appears promising for patients with severe illness.

Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.

No significant difference seen in five-, 10-day course for severe COVID-19 without mechanical ventilation.

Treatment with remdesivir was associated with a shorter time to recovery in patients hospitalized with coronavirus disease 2019 (COVID-19), according to peer-reviewed data published in the New England Journal of Medicine.

Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.

Treatment with inhaled nitric oxide has been shown to have both pulmonary and antiviral benefits.